306-07-0
基本信息
丙炔甲基苄胺
巴吉林盐酸盐
巴吉林,优降宁
优降宁 盐酸盐
盐酸帕吉林 标准品
N-甲基-N-炔丙基苄胺盐酸盐
N-甲基-N-丙炔基苄胺 盐酸盐
巴吉林盐酸盐,丙炔甲基苄胺,巴吉林
N-甲基-N-2-丙炔基苄胺 盐酸盐
pargyline hcl
Parguline HCL
pargylinechloride
PARGYLINE HYDROCHLOR
PARGYLINE HYDROCHLORIDE
Parglycine hydrochloride
Pargylamine hydrochloride
Pargyline Hydrochloride (200 mg)
PARGYLINE HYDROCHLORIDE USP/EP/BP
物理化学性质
| 熔点 | 160-163 °C(lit.) |
| 储存条件 | −20°C |
| 溶解度 | ≥33.55 mg/mL in EtOH; ≥51.6 mg/mL in H2O; ≥7.55 mg/mL in DMSO |
| 形态 | 结晶固体 |
| 颜色 | Crystals from EtOH/Et2O |
| 生物来源 | synthetic |
| 水溶解性 | water: 50mg/mL, clear, colorless to faintly yellow |
| Merck | 13,7110 |
| BRN | 3699487 |
| InChI | InChI=1S/C11H13N.ClH/c1-3-9-12(2)10-11-7-5-4-6-8-11;/h1,4-8H,9-10H2,2H3;1H |
| InChIKey | BCXCABRDBBWWGY-UHFFFAOYSA-N |
| SMILES | C1(=CC=CC=C1)CN(C)CC#C.Cl |
| CAS 数据库 | 306-07-0 |
安全数据
| 危险性符号(GHS) | ![]() GHS06 |
| 警示词 | 危险 |
| 危险性描述 | H301 |
| 防范说明 | P301+P310 |
| 危险品标志 | Xn |
| 危险类别码 | 22 |
| 安全说明 | 22-24/25 |
| 危险品运输编号 | UN 2811 6.1/PG 3 |
| WGK Germany | 3 |
| RTECS号 | DP6650000 |
| F | 10 |
| 危险等级 | 6.1(b) |
| 包装类别 | III |
| 海关编码 | 2921199990 |
| 毒性 | LD50 orl-rat: 250 mg/kg 27ZQAG -,401,72 |
应用领域
图谱信息
巴吉林,优降宁(306-07-0)质谱(MS)巴吉林,优降宁(306-07-0)核磁图(1HNMR)巴吉林,优降宁(306-07-0)核磁图(13CNMR)巴吉林,优降宁(306-07-0)红外图谱(IR1)巴吉林,优降宁(306-07-0)红外图谱(IR2)巴吉林,优降宁(306-07-0)Raman光谱优降宁盐酸盐价格(试剂级)
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2026/09/15 | HY-A0091R | 优降宁盐酸盐 Pargyline hydrochloride (Standard) | 306-07-0 | 10 mg | 270元 |
| 2026/09/15 | HY-A0091R | 优降宁盐酸盐 Pargyline hydrochloride (Standard) | 306-07-0 | 25 mg | 477元 |
| 2026/09/15 | HY-A0091R | 优降宁盐酸盐 Pargyline hydrochloride (Standard) | 306-07-0 | 50 mg | 720元 |
常见问题列表
| Target | Value |
|
MAO-B
(Cell-free assay) | 0.5 μM(Ki) |
|
MAO-A
(Cell-free assay) | 13 μM(Ki) |
Pargyline (0.5-2 mM; 24-120 hours; LNCaP-LN3 cells) treatment inhibits the proliferation of prostate cancer cells in a time- and dose-dependent manner.
Pargyline (0.5-2 mM; 24-48 hours; LNCaP-LN3 cells) treatment decreases S phase and increases the G1 phase in the cells in a dose-dependent manner.
Pargyline (0.5 mM; 24 hours; LNCaP-LN3 cells) treatment increases the apoptotic cells.
Pargyline (2 mM; 48 hours; LNCaP-LN3 cells) treatment induces an increase of cytochrome c and a decrease of caspase-3 in the cells, but does not lead to a change of BCL-2 expression.
Cell Proliferation Assay
| Cell Line: | LNCaP-LN3 cells |
| Concentration: | 0.5 mM, 1 mM, 1.5 mM or 2 mM |
| Incubation Time: | 24 hours, 48 hours, 72 hours, 96 hours or 120 hours |
| Result: | Inhibited the proliferation of prostate cancer cells in a time- and dose-dependent manner. |
Cell Cycle Analysis
| Cell Line: | LNCaP-LN3 cells |
| Concentration: | 0.5 mM, 2 mM |
| Incubation Time: | 24 hours, 48 hours |
| Result: | The S phase ratio of the cells was decreased, while their G1 phase ratio was increased. |
Apoptosis Analysis
| Cell Line: | LNCaP-LN3 cells |
| Concentration: | 0.5 mM |
| Incubation Time: | 24 hours |
| Result: | Increased the apoptotic cells. |
Western Blot Analysis
| Cell Line: | LNCaP-LN3 cells |
| Concentration: | 2 mM |
| Incubation Time: | 48 hours |
| Result: | Induced an increase of cytochrome c and a decrease of caspase-3. |
Pargyline (10 mg/kg; iv) treatment induces a moderate (about 20 mm Hg) but persistent (48 h) decrease of systolic blood pressure in unanesthetized adult spontaneously hypertensive rats (SHR) but not in normotensive rats.
A low dose of Pargyline (200 μg; icv) injected directly into the brain lowered arterial pressure. The hypotensive action of Pargylline in SHR appears to be the consequence of Norepinephrine accumulating at an inhibitory α-adrenoceptor in brain.
